Article: article from journal or magazin.
A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension.
Human Gene Therapy
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Current therapy for several forms of anemia involves a weekly regime of multiple subcutaneous injections of recombinant human erythropoietin (hEpo). In an effort to provide a physiologically regulated administration of erythropoietin, we are developing cell lines genetically engineered to release hEpo as a function of oxygen tension. C2C12 cells were transfected using a vector containing the hEpo cDNA driven by the hypoxia-responsive promoter to the murine phosphoglycerate kinase gene. In vitro, these cells showed a threefold increase in hEpo secretion as oxygen levels were shifted from 21% to 1.3% oxygen. To test in vivo response, C2C12-hEpo cells were encapsulated in a microporous membrane and implanted subcutaneously on the dorsal flank of DBA/2J mice. On average, serum hEpo levels in animals exposed to 7% oxygen were two-fold higher than values seen in their control counterparts kept at 21% oxygen. Similar studies employing rats confirmed that hEpo delivery is regulated as a function of oxygen tension. These results suggest the feasibility of developing an oxygen-regulated, encapsulated cell-based system for hEpo delivery.
Anemia/therapy, Animals, Anoxia/metabolism, Cells, Cultured, DNA-Binding Proteins/genetics, Drug Compounding, Erythropoietin, Recombinant/blood, Erythropoietin, Recombinant/genetics, Gene Expression Regulation, Gene Therapy/methods, Histocytochemistry, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit, Mice, Mice, Inbred DBA, Nuclear Proteins/genetics, Oxygen/blood, Oxygen/physiology, Partial Pressure, Phosphoglycerate Kinase/genetics, Plasmids/genetics, Promoter Regions, Genetic/genetics, Rats, Rats, Inbred F344, Transcription Factors, Transgenes
Web of science
Last modification date